Onc Now
In this episode of Onc Now, Mary Disis, Director of the University of Washington’s Medicine Cancer Vaccine Institute, Seattle, USA, explores the science and future of cancer vaccines. She discusses how vaccines fit into today’s immunotherapy landscape, the evolution of human epidermal growth factor receptor 2 (HER2)-targeted therapies, progress in breast cancer vaccines, the promise of cancer prevention, and the key priorities for survivorship and future oncology care.
Apple | Spotify | Amazon Music | Youtube
Speaker bio:
Mary Disis is the Director of the University of Washington’s Medicine Cancer Vaccine Institute, Seattle, USA, since 2017. Her work has been at the forefront of cancer immunology and translational oncology, with a particular focus on the development of cancer vaccines and immune-based therapies.
Timestamps:
00:00 – Introduction
01:28 – Cancer Vaccines Explained
03:57 – Journey Into Cancer Immunology
06:38 – Cancer Vaccines in Immunotherapy
10:02 – Leading the Cancer Vaccine Institute
13:26 – Progress in Breast Cancer Vaccines
18:39 – HER2 Research and Treatment Evolution
21:30 – Future of Preventive Cancer Vaccines
26:39 – Priorities for Cancer Survivorship
30:30 – Three Wishes for Oncology’s Future
Disclaimer: The opinions expressed in this episode belong to the speakers and do not necessarily represent the opinions of EMJ.
